Saturday, February 25, 2023 11:17:16 AM
Here’s my concern with acquiring Advent.
First, I believe it’s the correct thing to do in order to eliminate the related party conflicts of interest. And in fact may be required by other parties, such as Nasdaq/NYSE or institutional investors. But the fear is Linda Powers will use this transaction as a vehicle to enrich Toucan and herself by making NWBO purchase Advent at an inflated purchase price…after NWBO shareholders have effectively funded Advent and should have owned it outright from the start!
But there’s no way Linda Powers is handing over Advent without shareholders having to pay for it a second time. That’s how she rolls. So hopefully the Board and shareholders at the very least receive a fairness opinion from a reputable FA. Otherwise there will be another lawsuit in the offering; and even then there still might be one.
And as a sidebar, NWBO acquiring Advent is tacit admission that all the critics of the Toucan and Advent relationship have been right all along.
First, I believe it’s the correct thing to do in order to eliminate the related party conflicts of interest. And in fact may be required by other parties, such as Nasdaq/NYSE or institutional investors. But the fear is Linda Powers will use this transaction as a vehicle to enrich Toucan and herself by making NWBO purchase Advent at an inflated purchase price…after NWBO shareholders have effectively funded Advent and should have owned it outright from the start!
But there’s no way Linda Powers is handing over Advent without shareholders having to pay for it a second time. That’s how she rolls. So hopefully the Board and shareholders at the very least receive a fairness opinion from a reputable FA. Otherwise there will be another lawsuit in the offering; and even then there still might be one.
And as a sidebar, NWBO acquiring Advent is tacit admission that all the critics of the Toucan and Advent relationship have been right all along.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
